medigraphic.com
Colegio de Medicina Interna de México.

2006, Number 6

<< Back Next >>

Med Int Mex 2006; 22 (6)

Hypothalamic neurohormones: biological actions and clinical applications

Córdoba SU, Navarro ZJE, Durán PEG, Peralta CJA, Alexanderson REG

Language: Spanish
References: 35
Page: 514-524
PDF size: 263.56 Kb.


ABSTRACT

Roger Guillemin awarded Nobel Prize in Medicine for his idea that the pituitary secretion was controlled by the hypothalam, and for his investigation and isolation of the first hypothalamic hormones; later, they were characterized and denominated hypothalamics releasing factors. Mostly, they are peptides, except for the dopamin, that is a biogenic amine and constitutes the main factor inhibitor of the prolactin. Besides regulating the liberation of pituitary hormones, some of these factors control the cellular pituitary growth, differentiation, proliferation and hormonal synthesis. They have some peculiarities: they can act on one or more pituitary hormones, to exercise dual control, likewise as neurotransmisors or neurmoduladors, and to exercise in themselves control of negative feedback. Now they are available for investigation, and analogs have been synthesized for treatment of diverse illnesses. This revision focuses on the main releasing factors available, on their biological aspects and clinical application in order to give a general panorama about their potential use in clinical practices.


REFERENCES

  1. Guillemin R. Hypothalamic releasing factors. J Endocrinol 2005;184:11-28.

  2. Cheng CK, Leung CK. Molecular biology of GnRH-I, GnRH-II and their receptors in humans. Endocr Rev 2005;26:283-306.

  3. Kiesel LA, Rody A, Grebb RR, Szylagyi A. Clinical uses of GnRH analogues. Clin Endocrinol 2002;56:677-87.

  4. Soysal S, Soysal ME, Oser Z, Gul N, Gezgin T. The effects of post-surgical administracion of goserelin plus anastrozole compared to goserelin alone in patients whit severe endometriosis: a prospective randomized trial. Hum Reprod 2004;19(1):160-7.

  5. Palomba S, Russo T, Orio F, Nappi C. Effectiveness of combined GnRH analogue plus raloxifene in treatment of uterine leiomyomas. Hum Reprod 2002;17(12):3213-9.

  6. Di Carlo C, Palomba S. Use of leuprolide plus tibolone in the treatment of PMS. Fertil Steril 2001;75(2): 380-4.

  7. Weckermann R. Hormone therapy in prostate cancer. Eur Urol 2004;46:279-84.

  8. Chengalvala MV, Pelletier JC. GnRH agonist and antagonists in cancer therapy. Curr Med Chem Anti Canc Agents 2003;3:399-410.

  9. Freda PU, Reyes CM. Carbegoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary 2004;(7):21-30.

  10. Cozzi R, Attanasio R, Lodrini S. Carbegoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol 2004;(61):209-15.

  11. Casulari L, Naves LA, Mello PA. Nelson's syndrome: complete remission with carbegoline but not with bromocriptine or cyproheptadine treatment. Horm Res 2004;(62):300-5.

  12. Kilicdag EB, Tarim E, Bagis T, Erkanli S, Aslan. Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia. Int J Gynaecol Obstet 2004;(85):292-3.

  13. Sakazume S, Obata K, Takahashi E, Yoshino A, Murakami N, Sakuta R. Bromocriptine treatment of prolactinoma restores growth hormone secretion and causes a catch up growth in a prepubertal child. Eur J Pediatr 2004;(173):472-4.

  14. Luque RM, Kineman RD, Park S, Peng XD. Homologous and heterologous regulation of pituitary receptors for ghrelin and growth hormone releasing hormone. Endocrinology 2004;145:3182-89.

  15. Tannenbaum GS, Epelbaum J, Bowers CY. Interrelationship between the novel peptide ghrelin and somatostatin/growth hormona-releasing hormona in regulation of pulsatile growth hormone secretion. Endocrinology 2003;144:967-74.

  16. Baldelli R, Otero XL, Camina JP, Gualillo O. Growth hormone secretagogues as diagnostic tools in disease status. Endocrine 2001;14:95-99.

  17. Ehlers MR. Recombinant human GHRH (1-44) NH2. Endocrine 2001;14:137-41.

  18. Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E. The usefulness of combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab 2003;88:95-102.

  19. Maghnie M, Cavigioli F, Tinelli C, Autelli M, Arico M. GHRH plus arginine in the diagnosis of adquired GH deficiency of childhood-onset. J Clin Endocrinol Metab 2002;87:2740-4.

  20. Khorram O, Garthwaite M, Golos T. The influence of aging and sex hormones on expresion of growth hormone-releasing hormone in the human immune system. J Clin Endocrinol Metab 2001;86:3157-61.

  21. Groeft R. Corticotropin-releasing hormone (CRH)-induced thyrotropin release is directly mediated trough CRH receptor type 2 on thyrotropes. Endocrinology 2003;144:5537-44.

  22. Li XF, Bowe JE, Mitchell JC, Brain SD, Lightman SL. The role of the locus coeruleus in corticotropin-releasing hormone and stress-induced supresion of pulsatile luteinizing hormone secretion in the female rat. Endocrinology 2005;146:323-31.

  23. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M. Corticoesteroid insufficiency in acutely ill patients. N Engl J Med 2003;348:727-34.

  24. Silverman ES, Breault DT, Vallone J, Subramanian S, Yilmaz AD, Mathew S. Corticotropin releasing hormone deficiency increases allergen-induced airway inflammation in a mouse model of asthma. J Allergy Clin Immunol 2004;114:747-54.

  25. Moawad AH, Goldenberg RL, Mercer B, Meis PJ. The preterm prediction study. The value of alkaline phosphatase, a fetoprotein, plasma corticotropin releasing hormone and other markers for the prediction of spontaneus preterm birth. Am J Obstet Gynecol 2002;186:990-6.

  26. Florio P, Imperatore A, Sanseverino F. The measurement of maternal plasma corticotropin releasing factor (CRF) and CRF-binding protein improves the early predicition of preeclampsia. J Clin Endocrinol Metab 2004;89:4673-7.

  27. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-54.

  28. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87(7):3013-8.

  29. Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M. Efficacy of the long-acting octreotide formulation (octreotide-Lar) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 2001;88(6):2849-53.

  30. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3034-40.

  31. Jain R, Singh J, Perlman JH, Gershengorn MC. Synthesis and biology of new thyrotropin-releasing hormone (TRH) analogues. Bioorg Med Chem 2002;10:189-94.

  32. Gary KA, Sevarino GG, Yarbrough AJ, Prange J. The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: Implications for TRH-based therapeutics. J Pharmacol Exp Ther 2003;305:410-6.

  33. Sun Y, Lu X, Gershengorn MC. Protein-coupled receptor signalling in neuroendocrine systems. Thyrotropin-releasing hormone receptors: similarities and differences. J Mol Endocr 2003;30:87-97.

  34. Hinkle PM, Pekary AE, Senanayaki S. Role of TRH receptors as posible mediators of analeptic actions of TRH-like peptides. Brain Research 2002;935;59-64.

  35. Hartoft-Nielsen ML, Lange M, Rasmussen AK, Scherer S. Thyrotropin-releasing hormone stimulation test in patients with pituitary pathology. Horm Res 2004;61:53-57.




2020     |     www.medigraphic.com